Last updated: September 14, 2022
Sponsor: University of Monastir
Overall Status: Active - Recruiting
Phase
3
Condition
Atrial Fibrillation
Dysrhythmia
Chest Pain
Treatment
N/AClinical Study ID
NCT05540600
TN2022-NAT-I NS-86
Ages 18-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Any patient with atrial fibrillation naïve to ß-blocker and digoxin or patientsfollowed for Atrial fibrillation and discontinued all treatment for more than a week.
- Frequency Control Strategy Decided
- Age over 18 years
- Stable hemodynamic state
- No contraindication to digoxin or ß-blocker
Exclusion
Exclusion Criteria:
- Required rhythm control strategy
- Contraindication to one of the two
- Heart rate <60 BPM
- Clearance rénale <30 ml/mn
- Pregnant or breastfeeding woman
- Persistence of a resting heart rate > 110
- Severe comorbidity with decreased life expectancy (advanced neoplasia, largestroke...)
Study Design
Total Participants: 30
Study Start date:
September 12, 2022
Estimated Completion Date:
December 01, 2023
Study Description
Connect with a study center
Fattouma Bourguiba University hospital
Monastir,
TunisiaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.